An Efficacy and Safety Study of PH-10 Aqueous Hydrogel for the Treatment of Plaque Psoriasis

Provectus Biopharmaceuticals

Status and phase

Completed

Phase 2

Conditions

Psoriasis

Treatments

Drug: PH-10 (0.001% Rose Bengal)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00941278

PH-10-PS-22

Details and patient eligibility

About

PH-10 is an aqueous hydrogel formulation of rose bengal disodium (RB) for topical administration to the skin, and is being studied for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis. This phase 2 efficacy and safety study will assess topical PH-10 applied once daily to areas of mild to moderate plaque psoriasis.

Enrollment

30 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Men or women, age 18 or older.
Presence of mild to moderate plaque psoriasis on the trunk or extremities (excluding palms, soles, scalp, and facial or intertriginous areas).
Fitzpatrick skin type I-VI.
Written informed consent by the subject or legal guardian.

Exclusion criteria

Women of childbearing potential who are pregnant, attempting to conceive, not using effective contraception, or who are nursing an infant.
Subjects who have received PUVA or systemic antipsoriatic therapy (immunosuppressants, cytostatics, corticosteroids) within 28 days of study initiation (two weeks for methotrexate).
Subjects who have received UVB light therapy within 14 days of study initiation.
Subjects who have received topical antipsoriatic therapy (including corticosteroids, tar, anthralin or Vitamin D analogs) to the study plaque areas within 14 days of study initiation.
Subjects who have received agents posing a clinically significant risk of photosensitivity reaction within 5 half-lives of study initiation.
Subjects who have received any approved or investigational biologic drug therapy for psoriasis within 90 days or 5 half-lives of study initiation.
Subjects who have participated in a clinical research study within 28 days of study initiation.
Subjects with a history of porphyria, systemic lupus erythematosus or xeroderma pigmentosum.
Subjects with clinical conditions that, in the opinion of the Investigator may pose a health risk to the subject by being involved in the study or detrimentally affect regular follow-up of the subject.